Rallybio to Merge with Avenzo Therapeutics in Highly Dilutive Reverse Merger; Existing Shareholders to Own ~2.8%
Summary
Rallybio Corp announced a definitive reverse merger with Avenzo Therapeutics, resulting in massive dilution for existing Rallybio shareholders who will own only ~2.8% of the combined oncology-focused company.
Key Events
-
Definitive Reverse Merger Agreement
Rallybio Corp will acquire Avenzo Therapeutics, Inc. in a reverse merger. The combined company will be renamed Avenzo Therapeutics, Inc. and trade under the ticker "AVZO".
-
Extreme Dilution for Existing Shareholders
Pre-merger Rallybio equityholders are expected to own approximately 2.8% of the combined company, while Avenzo equityholders and new investors will own the remaining ~97.2%.
-
Substantial Concurrent Financing
Avenzo secured a $215.0 million private placement, expected to close immediately prior to the merger, to fund the combined company's operations into late 2028.
-
Complete Management and Strategic Change
Avenzo's leadership team will take over the combined company, with Rallybio's current executive officers and directors expected to resign. This marks a new strategic direction for Rallybio, following the recent termination of a previous reverse merger agreement.
Analysis
This filing details a definitive reverse merger agreement where Rallybio Corp will acquire Avenzo Therapeutics. Existing Rallybio shareholders will own only approximately 2.8% of the combined company, which will be renamed Avenzo Therapeutics, Inc. and focus on oncology therapies. This represents extreme dilution and a complete change in strategic direction and management for Rallybio. A concurrent $215 million private placement will fund the new entity's operations into late 2028, but the terms are highly unfavorable for current Rallybio equity. Rallybio shareholders will receive Contingent Value Rights (CVRs) for legacy assets, but their value is uncertain. This follows the recent termination of a previous merger agreement.
At the time of this filing, RLYB was trading at $14.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $76.6M. The 52-week trading range was $2.16 to $16.00. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.